Could one insulin shot a day be enough for gestational diabetes?
NCT ID NCT07171684
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether a single daily dose of long-acting insulin can control blood sugar as well as the usual regimen of long-acting insulin plus mealtime insulin in pregnant women with diabetes. About 176 participants will be randomly assigned to one of the two approaches and will share their blood sugar logs weekly for dose adjustments. The goal is to simplify treatment while ensuring safety for both mother and baby.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 176 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Nov 2025
- Expected to finish
-
May 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 50 years
- Sex
-
Female participants only
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Diagnosed with type 2 diabetes mellitus or A2 gestational diabetes mellitus requiring insulin use during pregnancy * Aged between 18-50 * Speak English or Spanish Exclusion Criteria: * Pre-existing use of insulin * Gestational Age \> or = 35w0d * Planning to follow-up with a doctor not associated with RWJ Barnabas or NYU Langone Health and/or deliver at a hospital other than RWJUH or NYU * Unwilling or unable to upload or email weekly blood sugar logs * Contraindication to Lispro or Lantus insulin, or patient chooses to not utilize insulin therapy * Fetal anomaly present
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Diabetes in pregnancy are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
2 sites. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Maternal-Fetal Medicine at NYU Langone Obstetrics & Gynecology Associates
NOT_YET_RECRUITINGNew York, New York, 10022, United States
-
Robert Wood Johnson Univeristy Hospital
RECRUITINGNew Brunswick, New Jersey, 08901, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New pill takes aim at stubborn blood sugar
- Gene therapy shots aim to save legs from amputation in diabetes
- New pill takes aim at blood sugar in diabetes
- Can AI-Tailored heat warnings shield chronic disease patients from dangerous temperatures?
- Weekly shot aims to melt away pounds in obesity fight
- Smart pillbox aims to keep patients on track